Targeted Radiopharmaceuticals Expansion: Ratio Therapeutics Secures $70 Million Series C Financing Backed by Eli Lilly and Bristol Myers Squibb

Key Development

U.S. clinical-stage radiopharmaceutical developer Ratio Therapeutics has officially closed a $70 million Series C financing round. The oversubscribed investment round drew strong backing from top-tier institutional and strategic biopharma investors: alongside existing participants Duquesne Family Office and Bristol Myers Squibb (BMY), the Series C introduced new corporate investors, including Eli Lilly and Company (LLY), Catalio Capital Management, and Wasatch Group.

Proceeds from the financing will be deployed across four primary strategic growth pillars:

1. Advancing the ATLAS Clinical Trial: Accelerating the Phase I/II ATLAS trial evaluating lead candidate [$^{225}\text{Ac}$]RTX-2358, a fibroblast activation protein (FAP)-targeted Alpha radiotherapeutic engineered for patients presenting with advanced sarcomas.

2. Submitting 5th IND Filing: Preparing an Investigational New Drug (IND) submission for its next-generation radioligand therapy candidate targeting gastrin-releasing peptide receptor (GRPR).

3. Pipeline & Platform Expansion: Applying proprietary Trillium™ and Macropa® platforms to engineer novel mono- and bispecific radioligand therapies targeting unaddressed solid tumor indications.

4. Scaling Manufacturing Infrastructure: Expanding its hybrid manufacturing architecture—combining a vertically integrated production site in Utah with diversified isotope sourcing contracts—to secure clinical and prospective commercial product supply.

Why It Matters

• The Clinical Shift Toward Actinium-225 ($^{225}\text{Ac}$) Alpha Emitters: Departing from traditional Beta-emitting isotopes ($^{177}\text{Lu}$), Alpha particles emitted by Actinium-225 transfer high Linear Energy Transfer (LET) over a short tissue path length (<10 cell diameters). This localized cytotoxic energy destroys double-stranded DNA within solid tumors while sparing adjacent healthy tissue.

• FAP as a Universal Radiotherapy Target: Fibroblast Activation Protein (FAP) is overexpressed on cancer-associated fibroblasts (CAFs) across multiple solid tumor microenvironments, particularly advanced sarcomas—an oncology indication with limited systemic treatment options.

• Strategic Backing from Big Pharma Majors (Eli Lilly & BMS): Co-investment from Bristol Myers Squibb (which acquired RayzeBio for $4.1 billion) and Eli Lilly (which acquired Point Biopharma for $1.4 billion) reinforces that targeted radiopharmaceuticals remain a central focus for pharmaceutical M&A.

• External Validation via Novartis Collaboration: Beyond its Series C round, Ratio Therapeutics validated its underlying technology platforms through a strategic co-development partnership with Novartis focused on somatostatin receptor type 2 (SSTR2) radioligand therapies.

Healthcare Insight Analysis

From the perspective of Healthcare Insight, Ratio Therapeutics’ $70 million Series C closing underscores The Targeted Alpha Therapy (TAT) Era across precision oncology.

Historically, developing small-molecule radiopharmaceuticals presented pharmacokinetic (PK) challenges: balancing rapid tumor localization with swift renal clearance to prevent radiation toxicity in healthy organs (such as the kidneys and bone marrow). Ratio Therapeutics mitigates these structural limitations using two proprietary platform technologies:

1. Trillium™ PK Tuning Platform: Enables precise customization of serum half-life and tumor retention properties, accelerating clearance from non-target tissues while maximizing radiation delivery to the tumor bed.

2. Macropa® Chelator Platform: Provides high-affinity chelation of Actinium-225, preventing free isotope release into systemic circulation and reducing off-target bone marrow toxicity risks.

Co-investment from Eli Lilly and BMS underscores a strategic focus on platform technology. Rather than acquiring late-stage single assets, major pharma players are securing early-stage positions in next-generation Targeted Alpha Therapy (TAT) platforms capable of addressing hard-to-treat solid tumors like sarcomas and refractory prostate cancers.

Market Implications

1. Intensifying M&A Competition in Radiopharmaceuticals: This financing round will encourage biopharma peers (such as AstraZeneca, Roche, and Novartis) to expand strategic acquisitions of early-stage biotechs advancing FAP- and GRPR-targeted radioligand platforms.

2. Securing Isotope Supply Infrastructure ($^{225}\text{Ac}$): Allocating capital to expand Ratio’s Utah facility and secure diversified supply contracts mitigates isotope supply bottlenecks associated with Actinium-225.

3. Expanding Clinical Options in Advanced Sarcomas: Successful advancement of [$^{225}\text{Ac}$]RTX-2358 in the ATLAS trial could deliver a first-in-class FAP-targeted radiotherapeutic for patients with advanced sarcomas, addressing a major unmet clinical need.

Strategic Ledger: Ratio Therapeutics Series C & Platform Matrix

Deal / Technical Component	Parameter Specifications	Strategic & Clinical Significance
Financing Round	$70 Million Series C	Funds clinical trials, pipeline expansion, and manufacturing.
Strategic Investors	Eli Lilly, BMS, Duquesne, Catalio, Wasatch	Strategic validation from leading biopharmaceutical entities.
Lead Clinical Asset	[$^{225}\text{Ac}$]RTX-2358 (Phase I/II ATLAS)	FAP-targeted Actinium-225 Alpha therapy for advanced sarcomas.
Core Platform Tech	Trillium™ (PK Tuning) & Macropa®	Optimizes radiopharmaceutical PK profiles and secures isotope chelation.
External Pharma Partner	Novartis	Strategic collaboration advancing SSTR2-targeted radioligands.

Source: https://www.pharmaceutical-technology.com/news/ratio-therapeutics-70m-funding-cancer-radiotherapy/?cf-view